Disitamab (CAS 2185868-98-6), also known as RC48-0, is a humanized monoclonal antibody that targets HER2, a protein overexpressed in certain cancers. It is used to make disitamab vedotin (RC48), an antibody-drug conjugate (ADC) for treating HER2-expressing cancers.
Key Features:
- Target Specificity: Binds to HER2 on cancer cells.
- Mechanism of Action: Inhibits HER2 signaling and delivers a cytotoxic drug to cancer cells.
- Molecular Characteristics: Humanized IgG1 monoclonal antibody.
Applications:
- Antibody-Drug Conjugates (ADCs): Used for targeted drug delivery.
- Cancer Therapy: Investigated for treating HER2-positive cancers like breast, gastric, and urothelial cancers.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
